DATE: 3-23-01		APPL. S.N.: <u>091 4/35, 576</u>		
TO EXAMINER: M. Williams	0N	ART UNIT: 16/6		
MOSE MONTGOMERY F	OOM ILE 18	MAILROOM DATE 3-9-0/		
AFTER FINAL YES NO NUMBER OF T.D(S). FILED NUMBER OF T.D(S). FILED Number of the submitted T.D. with the results as set forth below. If you agree, please use the appropriate form paragraphs identified by this informal memo in your next office action to notify applicant about the T.D. If you disagree with my analysis or have questions at all about the acceptability of the T.D., please see me or our Special Program Examiner. THIS MEMO IS AN INFORMAL, INTERNAL MEMO ONLY. IT MUST NOT BE MAILED TO APPLICANT, NOR SHOULD A COPY BE IN LEFT IN FILE.				
The T.D. is PROPER and has been record				
[] The T.D. is NOT PROPER and has not been accepted for the reason(s) checked below. (See 14.24).				
[] The recording fee of \$ has not been submitted nor is there any pre authorization in the application file to charge to a deposit account. (See 14.26.07)				
[] Application Examiner has not processed T.				
[] The T.D. does not satisfy Rule 321(b)(3) in that the person who has signed the T.D. has not stated his/her interest (and/or the extent of the interest of the business entity represented by the signature) in the application/patent. (See 14.26 and 14.26.01).				
[] The T.D. tacks the enforceable only during Rule 321(c). (See 14.27, 14.27.01).	the common owership c	ause needed to overcome a double patenting rejection,		
[] It is directed to a particular claims(s), which is not acceptable since "the disclaimer must be of a terminal portion of the term of the entire patent to be granted". MPEP 1490. (See 14.26, 14.26.02).				
[] The person who signed the terminal disclal [] has falled to state his/her capacity [] is not recognized as an officer of	/ to sign for the business	entity, (See 14.28). and possibly 14.29.01).		
and from anacified as to where such sudence	is recorded in the office.	r(s) to assignee has been submitted, nor is the reel 37 CFR 3.73(b). (See 1140 O.G. 72). <u>NOTE</u> : This and in the T.D. <u>or</u> in a seperate paper <u>submitted</u> by		
[] No "statement" specifying that the evidentia knowledge and belief the title is in the assignee	ry documents have been seeking to take action. 3	reviewed and that, to the best of the assignee's 7 CFR 3.73(b). (See 1140 O.G. 72) (See 14.31).		
[] The T.D. is not signed. (See 14.26, 14.26.)	3). or 14.26.03 if TD is n	ot signed by all the owners.		
[] Attorney not of record in oath/deci. or a sep	erate paper filed appointi	ng a new or associate attorney. (See 14.29.01).		
[] The serial number of the application (or the missing or incorrect. (See 14.32).	number of the patent) W	hich forms the basis for the double patenting is		
[] The serial number of this application (or the or incorrect. (See 14.26, 14.26.04 or 14.26.05).	number of the patent in	reexam or reissue case(s) being disclaimed is missing		
[] The period disclaimed is incorrect or not sp	ecified. (See 14.27, 14.2	7.2 or 14.27.3)(For Samples 14.27.04 and 14.27.05)		
[] Other:	<u> </u>			
Suggestion to request refund of \$	/See 14.35 14.36)			
		LOWANCE ANY OF THE ABOVE INFORMALTIES		
MAY BE FAXED IN TO THE GROUP	IN CONDITION FOR AL	LOTTANGE ANY ST. THE ASSOCIATION		
FOR SAMPLE TERMINAL DISCLA	MERS AND CERT	IFICATES:		
 Sample of a TD over a pending application and assignee Certificate (See 14.37). Sample of a TD over a prior patent and assignee Certificate (See 14.38). Sample Assignee Certificate under 37 CFR 3.73 (b) (See 14.39) 				





TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A PRIOR PATENT

Docket Number 300.1003

In re	Appl	lication	of:
-------	------	----------	-----

Chih-Ming CHEN, et al.

Application No.

09/435,576

Filed:

November 8, 1999

For:

HMG-COA REDUCTASE INHIBITOR EXTENDED RELEASE FORMULATION

The owner Andrx Corporation of 100% percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173, as presently shortened by any terminal disclaimer, of prior Patent No. 5.916.595. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

Check either box 1 or 2 below, if appropriate.

1.

For submission on behalf an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

2.

The undersigned is an attorney of record.

March 6, 2001

Robert J. Paradiso (Reg. No. 41,240) Typed or printed name

- ▼ Terminal disclaimer fee under 37 CFR 1.20(d) included.
- ☑ PTO suggested wording for terminal disclaimer was

⋈ unchanged. ☐ changed (if changed, an explanation should be supplied).
 >*Certification under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee.

03/12/2001 SSITHIB1 00000005 09435576

02 FC:148

110.00 DP

\$6